Severe acute respiratory syndrome vs. The Middle East respiratory syndrome

Current Opinion in Pulmonary Medicine

Volumn 20, Issue 3, 2014, Pages 233-241

  Hui, David S ^a   Memish, Ziad A ^b   Zumla, Alimuddin ^c,d  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b MINISTRY OF HEALTH   (Saudi Arabia)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

clinical features; MERS; MERS CoV; pathogenesis; respiratory tract infections; SARS; treatment

Indexed keywords

ALPHA2B INTERFERON; CORTICOSTEROID; CYCLOSPORIN A; DIPEPTIDYL PEPTIDASE IV; LOPINAVIR; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; RIBAVIRIN; RITONAVIR; ANTIVIRUS AGENT; INTERFERON;

ANTIVIRAL THERAPY; CLINICAL FEATURE; COMPARATIVE STUDY; CORONAVIRUS INFECTION; HUMAN; META ANALYSIS (TOPIC); MIDDLE EAST; MIDDLE EAST RESPIRATORY SYNDROME; RADIOGRAPHIC FEATURE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; VIRUS PATHOGENESIS; AGE DISTRIBUTION; ANIMAL; BAT; CAMEL; CORONAVIRUS; CORONAVIRUS INFECTIONS; CROSS INFECTION; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; FEMALE; IMMUNOLOGY; INCUBATION TIME; INNATE IMMUNITY; ISOLATION AND PURIFICATION; LUNG; MALE; PATHOGENICITY; PUBLIC HEALTH; RADIOGRAPHY; REAL TIME POLYMERASE CHAIN REACTION; SEX RATIO; VIROLOGY; VIRUS LOAD;

AGE DISTRIBUTION; ANIMALS; ANTIVIRAL AGENTS; CAMELS; CHIROPTERA; CORONAVIRUS; CORONAVIRUS INFECTIONS; CROSS INFECTION; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNITY, INNATE; INFECTIOUS DISEASE INCUBATION PERIOD; INTERFERONS; LUNG; MALE; MIDDLE EAST; MYCOPHENOLIC ACID; PUBLIC HEALTH; REAL-TIME POLYMERASE CHAIN REACTION; RIBAVIRIN; SEVERE ACUTE RESPIRATORY SYNDROME; SEX DISTRIBUTION; VIRAL LOAD;

EID: 84897578593     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0000000000000046     Document Type: Review

References (95)

1. Lee N, Hui DS, Wu A, et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003; 348:1986-1994.
2. Tsang KW, Ho PL, Ooi GC, et al. A cluster of cases of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003; 348:1977-1985.
3. Zhao Z, Zhang F, Xu M, et al. Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China. J Med Microbiol 2003; 52:715-720.
4. Xu RH, He JF, Evans MR, et al. Epidemiologic clues to SARS origin in China. Emerg Infect Dis 2004; 10:1030-1037.
5. Zhong NS, Zheng BJ, Li YM, et al. Epidemiology and cause of severe acute respiratory syndrome in Guangdong, People's Republic of China, in Feb 2003. Lancet 2003; 362:1353-1358.
6. Zaki AM, van Boheemen S, Bestebroer TM, et al. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012; 367:1814-1820.
7. Hijawi B, Abdallat M, Sayaydeh A, et al. Novel coronavirus infections in Jordan, April 2012: epidemiological findings from a retrospective investigation. East Mediterr Health J 2013; 19 (Suppl. 1):S12-S18.
8. World Health Organization. Middle East respiratory syndrome coronavirus (MERS-CoV) -update. Disease outbreak news. Available at http://www.who.int/csr/ don/2014-01-09/en/index.html. [Accessed 21 January 2014].
9. Peiris JS, Lai ST, Poon LL, et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 2003; 361:1319-1325.
10. Kuiken T, Fouchier RA, Schutten M, et al. Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet 2003; 362:263-270.
11. Drosten C, Gunther S, Preiser W, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 2003; 348:1967-1976.
12. Ksiazek TG, Erdman D, Goldsmith CS, et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 2003; 348:1953-1966.
13. Du L, Qiu JC, Wang M, et al. Analysis on the characteristics of blood serum Ab-IgG detective result of severe acute respiratory syndrome patients in Guangzhou, China. Zhonghua Liu Xing Bing Xue Za Zhi 2004; 25: 925-928.
14. Guan Y, Zheng BJ, He YQ, et al. Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science 2003; 302:276-278.
15. Wang M, Yan M, Xu H, et al. SARS-CoV infection in a restaurant from palm civet. Emerg Infect Dis 2005; 11:1860-1865.
16. Song HD, Tu CC, Zhang GW, et al. Cross-host evolution of severe acute respiratory syndrome coronavirus in palm civet and human. Proc Natl Acad Sci USA 2005; 102:2430-2435.
17. Lau SK, Woo PC, Li KS, et al. Severe acute respiratory syndrome coronaviruslike virus in Chinese horseshoe bats. Proc Natl Acad Sci USA 2005; 102:14040-14045.
18. Li W, Shi Z, Yu M, et al. Bats are natural reservoirs of SARS-like coronaviruses. Science 2005; 310:676-679.
19. Shi Z, Hu Z. A review of studies on animal reservoirs of the SARS coronavirus. Virus Res 2008; 133:74-87.
20. Annan A, Baldwin HJ, Corman VM, et al. Human betacoronavirus 2c EMC/2012-related viruses in bats, Ghana and Europe. Emerg Infect Dis 2013; 19:456-459.
21. Memish ZA, Mishra N, Olival KJ, et al. Middle East respiratory syndrome coronavirus in bats, Saudi Arabia. Emerg Infect Dis 2013; 19:1819-1823.
22. Reusken CB, Haagmans BL, Muller MA, et al. Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study. Lancet Infect Dis 2013; 13:859-866.
23. Haagmans BL, Al Dhahiry SH, Reusken CB, et al. Middle East respiratory syndrome coronavirus in dromedary camels: an outbreak investigation. Lancet Infect Dis 2013; 14:140-145.
24. Cotten M, Watson SJ, Kellam P, et al. Transmission and evolution of the Middle East respiratory syndrome coronavirus in Saudi Arabia: a descriptive genomic study. Lancet 2013; 382:1993-2002.
25. Hsu LY, Lee CC, Green JA, et al. Severe acute respiratory syndrome in Singapore: clinical features of index patient and initial contacts. Emerg Infect Dis 2003; 9:713-717.
26. Booth CM, Matukas LM, Tomlinson GA, et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA 2003; 289:2801-2809.
27. WHO. Summary of probable SARS cases with onset of illness from 1 November to 31 July 2003. Available from http://www.who.int/csr/sars/country/table2003- 09-23/en.
28. Peiris JS, Yuen KY, Osterhaus AD, et al. The severe acute respiratory syndrome. N Engl J Med 2003; 349:2431-2441.
29. Wong RS, Hui DS. Index patient and SARS outbreak in Hong Kong. Emerg Infect Dis 2004; 10:339-341.
30. Loon SC, Teoh SC, Oon LL, et al. The severe acute respiratory syndrome coronavirus in tears. Br J Ophthalmol 2004; 88:861-863.
31. Yu IT, Li Y, Wong TW, et al. Evidence of airborne transmission of the severe acute respiratory syndrome virus. N Engl J Med 2004; 350:1731-1739.
32. Chu CM, Cheng VC, Hung IF, et al. Viral load distribution in SARS outbreak. Emerg Infect Dis 2005; 11:1882-1886.
33. Yu IT, Qiu H, Tse LA, Wong TW. Severe acute respiratory syndrome beyond Amoy Gardens: completing the incomplete legacy. Clin Infect Dis 2013; 58:683-686.
34. Booth TF, Kournikakis B, Bastien N, et al. Detection of airborne severe acute respiratory syndrome (SARS) coronavirus and environmental contamination in SARS outbreak units. J Infect Dis 2005; 191:1472-1477.
35. Yu IT, Wong TW, Chiu YL, et al. Temporal-spatial analysis of severe acute respiratory syndrome among hospital inpatients. Clin Infect Dis 2005; 40:1237-1243.
36. TheWHOMERS-CoV Research Group. State of knowledge and data gaps of Middle East respiratory syndrome coronavirus (MERS-CoV) in humans. PLoS Curr 2013; 5:. doi: 10.1371/currents.outbreaks.0bf719e352e7478f8ad85 fa30127ddb8.
37. Assiri A, McGeer A, Perl TM, et al. Hospital outbreak of Middle East respiratory syndrome coronavirus. N Engl J Med 2013; 369:407-416.
38. Assiri A, Al-Tawfiq JA, Al-Rabeeah AA, et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis 2013; 13:752-761.
39. Memish ZA, Zumla AI, Al-Hakeem RF, et al. Family cluster of Middle East respiratory syndrome coronavirus infections. N Engl J Med 2013; 368:2487-2494.
40. Leung GM, Hedley AJ, Ho LM, et al. The epidemiology of severe acute respiratory syndrome in the 2003 Hong Kong epidemic: an analysis of all 1755 patients. Ann Intern Med 2004; 141:662-673.
41. Leung WK, To KF, Chan PK, et al. Enteric involvement of severe acute respiratory syndrome-associated coronavirus infection. Gastroenterology 2003; 125:1011-1017.
42. Hung EC, Chim SS, Chan PK, et al. Detection of SARS coronavirus RNA in the cerebrospinal fluid of a patient with severe acute respiratory syndrome. Clin Chem 2003; 49:2108-2109.
43. Lau KK, Yu WC, Chu CM, et al. Possible central nervous system infection by SARS coronavirus. Emerg Infect Dis 2004; 10:342-344.
44. Wong KC, Leung KS, Hui M. Severe acute respiratory syndrome (SARS) in a geriatric patient with a hip fracture. A case report. J Bone Joint Surg 2003; 85A:1339-1342.
45. Hon KL, Leung CW, Cheng WT, et al. Clinical presentations and outcome of severe acute respiratory syndrome in children. Lancet 2003; 561:1701-1703.
46. Wong SF, Chow KM, Leung TN, et al. Pregnancy and perinatal outcomes of women with severe acute respiratory syndrome. Am J Obstet Gynecol 2004; 191:292-297.
47. Leung GM, Lim WW, Ho LM, et al. Seroprevalence of IgG antibodies to SARS-coronavirus in asymptomatic or subclinical population groups. Epidemiol Infect 2006; 134:211-221.
48. Hui DS, Wong KT, Antonio GE, et al. Severe acute respiratory syndrome (SARS): correlation of clinical outcome and radiological features. Radiology 2004; 233:579-585.
49. Hui DS, Wong PC, Wang C. Severe acute respiratory syndrome: clinical features and diagnosis. Respirology 2003; 8:S20-S24.
50. Peiris JS, Chu CM, Cheng VC, et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 2003; 361:1767-1772.
51. Guery B, Poissy J, el Mansouf L, et al. Clinical features and viral diagnosis of two cases of infection with Middle East respiratory syndrome coronavirus: a report of nosocomial transmission. Lancet 2013; 381:2265-2272.
52. Hui DS, Sung JJ. Severe acute respiratory syndrome. Chest 2003; 124:12-15.
53. Wong GW, Hui DS. Severe acute respiratory syndrome: epidemiology, diagnosis and treatment. Thorax 2003; 58:558-560.
54. Wong RS, Wu A, To KF, et al. Haematological manifestations in patients with severe acute respiratory syndrome: retrospective analysis. BMJ 2003; 326:1358-1362.
55. Drosten C, Seilmaier M, Corman VM, et al. Clinical features and virological analysis of a case of Middle East respiratory syndrome coronavirus infection. Lancet Infect Dis 2013; 13:745-751.
56. Wong KT, Antonio GE, Hui DS, et al. Severe acute respiratory syndrome: radiographic appearances and pattern of progression in 138 patients. Radiology 2003; 228:401-406.
57. Chan PK, To KF, Lo AW, et al. Persistent infection of SARS coronavirus in colonic cells in vitro. J Med Virol 2004; 74:1-7.
58. Simmons G, Gosalia DN, Rennekamp AJ, et al. Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. Proc Natl Acad Sci USA 2005; 102:11876-11881.
59. Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003; 426:450-454.
60. Hamming I, Timens W, Bulthuis ML, et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol 2004; 203:631-637.
61. Imai Y, Kuba K, Rao S, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 2005; 436:112-116.
62. Law PT, Wong CH, Au TC, et al. The 3a protein of severe acute respiratory syndrome-associated coronavirus induces apoptosis in Vero E6 cells. J Gen Virol 2005; 86:1921-1930.
63. Tan YJ, Fielding BC, Goh PY, et al. Over expression of 7a, a protein specifically encoded by the severe acute respiratory syndrome coronavirus, induces apoptosis via a caspase-dependent pathway. J Virol 2004; 78: 14043-14047.
64. Raj VS, Mou H, Smits SL, et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 2013; 495:251-254. An interesting study of the functional receptor of MERS-CoV.
65. Lu G, Hu Y, Wang Q, et al. Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature 2013; 500:227-231.
66. Muller MA, Raj VS, Muth D, et al. Human coronavirus EMC does not require the SARS-coronavirus receptor and maintains broad replicative capability in mammalian cell lines. mBio 2012; 3: e00515-12.
67. Chan JF, Chan KH, Choi GK, et al. Differential cell line susceptibility to the emerging novel human betacoronavirus 2c EMC/2012: implications for disease pathogenesis and clinical manifestation. J Infect Dis 2013; 207: 1743-1752.
68. De Wilde AH, Raj VS, Oudshoorn D, et al. MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-A treatment. J Gen Virol 2013; 94:1749-1760.
69. Falzarano D, de Wit E, Martellaro C, et al. Inhibition of novel b coronavirus replication by a combination of interferon-a2b and ribavirin. Sci Rep 2013; 3:1686.
70. Chan RW, Chan MC, Agnihothram S, et al. Tropism of and innate immune responses to the novel human betacoronavirus lineage C virus in human ex vivo respiratory organ cultures. J Virol 2013; 87:6604-6614.
71. Van Boheemen S, de Graaf M, Lauber C, et al. Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. mBio 2012; 3: e00473-12.
72. Kopecky-Bromberg SA, Marti'nez-Sobrido L, Frieman M, et al. Severe acute respiratory syndrome coronavirus open reading frame (ORF) 3b, ORF 6, and nucleocapsid proteins function as interferon antagonists. J Virol 2007; 81:548-557.
73. Josset L, Menachery VD, Gralinski LE, et al. Cell host response to infection with novel human coronavirus EMC predicts potential antivirals and important differences with SARS coronavirus. mBio 2013; 4:e00165-13.
74. Tao X, Hill TE, Morimoto C, et al. Bilateral entry and release of Middle East respiratory syndrome coronavirus induces profound apoptosis of human bronchial epithelial cells. J Virol 2013; 87:9953-9958.
75. Stroher U, DiCaro A, Li Y, et al. Severe acute respiratory syndrome-related coronavirus is inhibited by interferon-a. J Infect Dis 2004; 189:1164-1167.
76. Chu CM, Cheng VC, Hung IF, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 2004; 59:252-256.
77. Chan KS, Lai ST, Chu CM, et al. Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicenter retrospective matched cohort study. Hong Kong Med J 2003; 9:399-406.
78. Cinatl J, Morgenstern B, Bauer G, et al. Treatment of SARS with human interferons. Lancet 2003; 362:293-294.
79. Hensley LE, Fritz LE, Jahrling PB, et al. Interferon-b 1a and SARS coronavirus replication. Emerg Infect Dis 2004; 10:317-319.
80. Haagmans BL, Kuiken T, Martina BE, et al. Pegylated interferon-A protects type 1 pneumocytes against SARS coronavirus infection in macaques. Nat Med 2004; 10:290-293.
81. Loutfy MR, Blatt LM, Siminovitch KA, et al. Interferon Alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. JAMA 2003; 290:3222-3228.
82. Tse GM, To KF, Chan PK, et al. Pulmonary pathological features in coronavirus associated severe acute respiratory syndrome (SARS). J Clin Pathol 2004; 57:260-265.
83. Wong CK, Lam CW, Wu AK, et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol 2004; 136:95-103.
84. Jiang Y, Xu J, Zhou C, et al. Characterization of cytokine/chemokine profiles of severe acute respiratory syndrome. Am J Respir Crit Care Med 2005; 171: 850-857.
85. Sung JJ, Wu A, Joynt GM, et al. Severe acute respiratory syndrome: report of treatment and outcome after a major outbreak. Thorax 2004; 59:414-420.
86. Tsang OT, Chau TN, Choi KW, et al. Coronavirus-positive nasopharyngeal aspirate as predictor for severe acute respiratory syndrome mortality. Emerg Infect Dis 2003; 9:1381-1387.
87. Wang H, Ding Y, Li X, et al. Fatal aspergillosis in a patient with SARS who was treated with corticosteroids. N Engl J Med 2003; 349:507-508.
88. Griffith JF, Antonio GE, Kumta SM, et al. Osteonecrosis of hip and knee in patients with severe acute respiratory syndrome treated with steroids. Radiology 2005; 235:168-175.
89. Lee N, Allen Chan KC, Hui DS, et al. Effects of early corticosteroid treatment on plasma SARS-associated coronavirus RNA concentrations in adult patients. J Clin Virol 2004; 31:304-309.
90. Cheng Y, Wong R, Soo YO, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis 2005; 24:44-46.
91. Chan JF, Chan KH, Kao RY, et al. Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus. J Infect 2013; 67:606-616. An interesting study of potential antiviral agents against MERS-CoV.
92. Falzarano D, de Wit E, Rasmussen AL, et al. Treatment with interferon-a2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat Med 2013; 19:1313-1317.
93. Al-Tawfiq JA, Momattin H, Dib J, Memish ZA. Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study. Int J Infect Dis 2014. [Epub ahead of print]
94. Breban R, Riou J, Fontanet A. Interhuman transmissibility of Middle East respiratory syndrome coronavirus: estimation of pandemic risk. Lancet 2013; 382:694-699.
95. Hui DS, Zumla A. Advancing priority research on the Middle East respiratory syndrome coronavirus. J Infect Dis 2014; 209:173-176.